123 related articles for article (PubMed ID: 31263028)
1. Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond.
Willis JA; Overman MJ; Vilar E
Clin Cancer Res; 2019 Sep; 25(17):5185-5187. PubMed ID: 31263028
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors.
Llosa NJ; Luber B; Tam AJ; Smith KN; Siegel N; Awan AH; Fan H; Oke T; Zhang J; Domingue J; Engle EL; Roberts CA; Bartlett BR; Aulakh LK; Thompson ED; Taube JM; Durham JN; Sears CL; Le DT; Diaz LA; Pardoll DM; Wang H; Anders RA; Housseau F
Clin Cancer Res; 2019 Sep; 25(17):5250-5259. PubMed ID: 31061070
[TBL] [Abstract][Full Text] [Related]
3. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
Kather JN; Halama N; Jaeger D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
[TBL] [Abstract][Full Text] [Related]
4. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
5. Inducing Hypermutability to Promote Anti-PD-1 Therapy Response.
Willis JA; Overman MJ
Cancer Discov; 2022 Jul; 12(7):1612-1614. PubMed ID: 35791694
[TBL] [Abstract][Full Text] [Related]
6. Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients.
Liu SS; Yang YZ; Jiang C; Quan Q; Xie QK; Wang XP; He WZ; Rong YM; Chen P; Yang Q; Yang L; Zhang B; Xia XJ; Kong PF; Xia LP
J Transl Med; 2018 Jul; 16(1):195. PubMed ID: 30005666
[TBL] [Abstract][Full Text] [Related]
7. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.
Overman MJ; Ernstoff MS; Morse MA
Am Soc Clin Oncol Educ Book; 2018 May; 38():239-247. PubMed ID: 30231358
[TBL] [Abstract][Full Text] [Related]
8. Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy.
IJsselsteijn ME; Sanz-Pamplona R; Hermitte F; de Miranda NFCC
Mol Aspects Med; 2019 Oct; 69():123-129. PubMed ID: 31136750
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers.
Zlobec I; Minoo P; Terracciano L; Baker K; Lugli A
Histopathology; 2011 Sep; 59(3):482-95. PubMed ID: 22034888
[TBL] [Abstract][Full Text] [Related]
10. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
Minoo P; Baker K; Baumhoer D; Terracciano L; Lugli A; Zlobec I
Hum Pathol; 2010 Jan; 41(1):70-8. PubMed ID: 19740518
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.
Lugli A; Vlajnic T; Giger O; Karamitopoulou E; Patsouris ES; Peros G; Terracciano LM; Zlobec I
Hum Pathol; 2011 Dec; 42(12):1833-40. PubMed ID: 21664647
[TBL] [Abstract][Full Text] [Related]
13. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer.
Giordano G; Parcesepe P; D'Andrea MR; Coppola L; Di Raimo T; Remo A; Manfrin E; Fiorini C; Scarpa A; Amoreo CA; Conciatori F; Milella M; Caruso FP; Cerulo L; Porras A; Pancione M
J Exp Clin Cancer Res; 2019 Jan; 38(1):28. PubMed ID: 30670049
[TBL] [Abstract][Full Text] [Related]
14. Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics.
Jones D; Guan JJ; Calagua C; Hansel DE; Epstein JI; Ye H
Hum Pathol; 2019 Dec; 94():58-63. PubMed ID: 31666198
[TBL] [Abstract][Full Text] [Related]
15. Tumor Grade Is Prognostically Relevant Among Mismatch Repair Deficient Colorectal Carcinomas.
Johncilla M; Chen Z; Sweeney J; Yantiss RK
Am J Surg Pathol; 2018 Dec; 42(12):1686-1692. PubMed ID: 30179899
[TBL] [Abstract][Full Text] [Related]
16. Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer.
Pietrantonio F; Randon G; Romagnoli D; Di Donato S; Benelli M; de Braud F
Cancer Treat Rev; 2020 Jan; 82():101935. PubMed ID: 31821983
[TBL] [Abstract][Full Text] [Related]
17. Cell-free DNA blood levels in colorectal cancer patients do not correlate with mismatch repair-proficiency.
Lazarev I; Leibovitch L; Czeiger D; Sion-Vardi N; Geffen DB; Douvdevani A; Ariad S
In Vivo; 2014; 28(3):349-54. PubMed ID: 24815837
[TBL] [Abstract][Full Text] [Related]
18. The Negative Impact of Body Mass Index on the Tumor Microenvironment in Colon Cancer: Results of a Prospective Trial.
Flaherty DC; Jalas JR; Sim MS; Stojadinovic A; Protic M; Lee DJ; Bilchik AJ
Ann Surg Oncol; 2018 May; 25(5):1374-1380. PubMed ID: 29532344
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.
Link JT; Overman MJ
Cancer J; 2016; 22(3):190-5. PubMed ID: 27341597
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]